Rate My Professor Andrew Morokoff

At the University of Melbourne, Associate Professor Morokoff heads the Brain Tumours and Epilepsy research group in the Melbourne Medical School. His research interests encompass the neurobiology of brain tumours, particularly gliomas; discovery of serum biomarkers including microRNAs and circulating tumour DNA for glioma diagnosis and post-operative monitoring; the role of glioma stem cells and their genotypes in tumour progression; utilisation of stem cell organoid cultures to identify molecular-targeted therapies; and the neuroscience underlying epileptic seizures induced by brain tumours, with emphasis on glutamate neurotransmitters. He maintains an active research laboratory and has authored over 70 publications. Key works include "Prediction of seizure likelihood with a long-term, implanted seizure advisory system in patients with drug-resistant epilepsy: a first-in-man study" published in The Lancet Neurology in 2013, "Motor neuroprosthesis implanted with neurointerventional surgery improves capacity for activities of daily living tasks in severe paralysis: first in-human experience" in the Journal of Neurointerventional Surgery in 2021, "Glutamate is associated with a higher risk of seizures in patients with gliomas" in Neurology in 2012, and "VDAC2 enables BAX to mediate apoptosis and limit tumor development" in Nature Communications in 2018. His research involves collaborations within the Parkville Precinct, including WEHI, Peter MacCallum Cancer Centre, and the Florey Institute, as well as international partners in Israel, the UK, and Canada.